ADMA Biologics (NASDAQ:ADMA) Given Overweight Rating at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of ADMA Biologics (NASDAQ:ADMA) in a research note released on Friday, Benzinga reports. Cantor Fitzgerald currently has a $20.00 price target on the biotechnology company’s stock.

A number of other equities analysts also recently commented on ADMA. Mizuho raised their target price on shares of ADMA Biologics from $12.00 to $14.00 and gave the company a buy rating in a research note on Thursday, June 20th. HC Wainwright raised their target price on shares of ADMA Biologics from $10.00 to $18.00 and gave the company a buy rating in a research note on Monday, August 12th. One analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of Buy and a consensus price target of $15.50.

ADMA Biologics Stock Performance

NASDAQ:ADMA opened at $20.03 on Friday. The company has a quick ratio of 2.80, a current ratio of 6.87 and a debt-to-equity ratio of 0.74. The company has a market cap of $4.64 billion, a P/E ratio of -1,001.50 and a beta of 0.61. ADMA Biologics has a fifty-two week low of $3.06 and a fifty-two week high of $20.16. The firm’s 50 day moving average is $15.90 and its two-hundred day moving average is $11.10.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Thursday, August 8th. The biotechnology company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.05. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. The business had revenue of $107.20 million for the quarter, compared to the consensus estimate of $86.44 million. During the same quarter last year, the firm posted ($0.02) EPS. The business’s revenue for the quarter was up 78.4% compared to the same quarter last year. Analysts expect that ADMA Biologics will post 0.49 EPS for the current year.

Insiders Place Their Bets

In other news, Director Young Kwon sold 60,000 shares of the firm’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $18.26, for a total value of $1,095,600.00. Following the transaction, the director now directly owns 241,441 shares in the company, valued at approximately $4,408,712.66. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, Director Young Kwon sold 60,000 shares of the stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $18.26, for a total transaction of $1,095,600.00. Following the sale, the director now directly owns 241,441 shares in the company, valued at approximately $4,408,712.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Lawrence P. Guiheen sold 9,000 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $18.47, for a total value of $166,230.00. Following the completion of the sale, the director now directly owns 153,941 shares in the company, valued at $2,843,290.27. The disclosure for this sale can be found here. Insiders sold a total of 466,900 shares of company stock valued at $8,224,121 over the last 90 days. 3.70% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Quest Partners LLC bought a new position in ADMA Biologics in the 2nd quarter worth approximately $29,000. EntryPoint Capital LLC acquired a new position in shares of ADMA Biologics during the first quarter valued at $31,000. Simplicity Wealth LLC acquired a new position in shares of ADMA Biologics during the first quarter valued at $68,000. Oxford Asset Management LLP bought a new stake in shares of ADMA Biologics during the fourth quarter valued at about $83,000. Finally, CWM LLC lifted its holdings in ADMA Biologics by 114.2% in the second quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock worth $92,000 after purchasing an additional 4,367 shares during the period. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.